A first prescription for diabetes can seem a modest thing, yet it quietly commits a household to a long rhythm of daily tablets, testing, and periodic checks for damage that may surface years later. Across India, families meet this rhythm with their own savings, and the gap between what public and private care costs is wide enough to shape who keeps up and who falls behind. Clinicians in Bengaluru and Chennai see the strain at their consultation desks, where patients ration doses or arrive without the reports that would guide their care. The larger question the report raises is whether ordinar
Diabetes Is Lifelong, and So Are the Bills: Can Indian Families Sustain Treatment?
Patients skip doses, delay tests or stop treatment, and complications can lead to dialysis, retinopathy procedures, amputation and lost wages for families.
Affording a prescription is only one part of the problem.
Mark
The headline numbers are about hospital stays. Is that really where diabetes costs sit?
Mimi
Mostly not. The doctors stress that most spending is outpatient: medicines, tests, consultations. That's why Dr Nishchitha wants financial protection schemes to cover outpatient care.
Luke
Worth being clear about the survey figures, though. They cover a single treated spell, such as 15 days, not a year of diabetes care, and the category is broader than diabetes alone.
Mark
So the monthly figures come from elsewhere?
Mimi
From the doctors' own estimates. Dr Praveen says ₹2,000-5,000 a month for urban outpatients, and Dr Nishchitha and Dr Ravikiran give drug-level ranges.
Luke
Those are individual clinicians' estimates, not measured national data. They're useful, but they differ by city, hospital and regimen.
Mark
What does rationing look like in practice?
Mimi
Skipped doses, tablets on alternate days, and consultations with only a fasting glucose reading instead of HbA1c or kidney reports.
Luke
The article describes these as tendencies the doctors observe. It gives no figure for how many patients do this.
Mark
And the way out?
Mimi
Generics, subsidised insulin, primary care that bundles screening. The aim, as Dr Nishchitha puts it, is the most effective treatment a patient can keep taking.
Luke
Fair, but the piece doesn't show that any of those measures would work at scale. They're recommendations.
Der Puls
- A single diabetes prescription can grow into a lifelong obligation that families must fund month after month, with no clear end in sight.
- Private hospital stays for endocrine conditions average about 8.5 times the cost of government care, pushing households toward debt or hard choices.
- Patients are skipping doses, stretching tablets across alternate days, or going without HbA1c and kidney tests because they cannot afford both medicine and monitoring.
- Clinicians warn of a vicious circle in which poorly controlled sugar fuels complications, and complications in turn drive costs far beyond routine treatment.
- Experts are pressing for affordable quality generics, subsidised insulin, and routine screening folded into primary care to head off expensive crises.
A first prescription for diabetes can seem a modest thing, yet it quietly commits a household to a long rhythm of daily tablets, testing, and periodic checks for damage that may surface years later. Across India, families meet this rhythm with their own savings, and the gap between what public and private care costs is wide enough to shape who keeps up and who falls behind. Clinicians in Bengaluru and Chennai see the strain at their consultation desks, where patients ration doses or arrive without the reports that would guide their care. The larger question the report raises is whether ordinary households can carry such a cost across decades, or whether the country's health system will have to take more of that weight onto its shoulders.
A first prescription for Type 2 diabetes looks like a small expense, but it opens a cycle of spending that has no scheduled end. Daily tablets, regular sugar checks, and repeated scans for damage to the kidneys, eyes, heart and nerves all accumulate, and those who move to insulin add needles, strips and supplies on top. A report from The South First, drawing on national survey data and clinicians in Bengaluru and Chennai, asks whether Indian households can keep paying for all of it over decades.
The National Sample Survey's 80th round shows the gap between public and private care starkly. A hospital stay for endocrine and metabolic conditions averaged ₹6,062 at government facilities and ₹51,258 at private ones, about 8.5 times as much. Southern states vary widely, with Andhra Pradesh and Kerala running well above Telangana and Tamil Nadu. These figures describe single treated spells rather than a lifetime of care, but they reveal how sharply costs diverge depending on where a patient walks in.
Clinicians put monthly figures to the burden. Basic oral treatment may cost a few hundred rupees, while insulin with monitoring can reach several thousand, and urban Type 2 patients often spend ₹2,000 to ₹5,000 a month, rising to ₹15,000 on advanced regimens. When money runs short, patients ration: they skip doses, stretch tablets, or come to hospital without the reports doctors need. One doctor describes families choosing between medicines and tests, a choice that makes complications more likely and care more expensive still.
The path forward, the clinicians suggest, lies in well-studied generics where clinically suitable, insulin that stays affordable and storable, and routine screening for heart, kidney, eye and foot problems built into primary care. Complications bring their own weight, from costly eye injections and dialysis to amputation and lost wages for daily workers. The open question is whether families can sustain this spending for decades, or whether the system must carry more of it.
A first prescription for Type 2 diabetes looks like a small expense. In practice it opens a cycle of spending that has no scheduled end: tablets every day, regular blood sugar checks, and repeated tests for damage to the kidneys, eyes, heart and nerves. People who move on to insulin pay for needles, testing strips and other supplies on top of the medicine itself. A report from The South First, drawing on national survey data and interviews with clinicians in Bengaluru and Chennai, asks whether Indian households can keep paying for all of it over decades.
The National Sample Survey's 80th round gives a rough outline of what households spend on endocrine, metabolic and nutritional conditions, the category that covers diabetes. For hospitalisation, the average across India was ₹32,269 per case over the previous 365 days. Government hospitals averaged ₹6,062 and private hospitals ₹51,258, about 8.5 times as much. For treatment without hospital admission, the average over a 15-day spell was ₹810: ₹219 at government hospitals, ₹1,283 at private hospitals and ₹927 at private clinics.
Southern states differ widely. Average hospitalisation spending was ₹62,306 in Andhra Pradesh, ₹39,129 in Karnataka, ₹42,443 in Kerala, ₹33,519 in Tamil Nadu and ₹27,286 in Telangana. For non-hospital care over 15 days, the figures were ₹792 in Andhra Pradesh, ₹380 in Karnataka, ₹419 in Kerala, ₹559 in Tamil Nadu and ₹946 in Telangana. Within Telangana, private hospitals averaged ₹2,038 and government hospitals ₹71. The report is careful to say these numbers describe a single treated spell, not a year or a lifetime of diabetes care, though they show how far public and private costs diverge.
Clinicians offered monthly estimates. Dr Nishchitha K of Gleneagles BGS Hospital, Bengaluru, puts basic oral treatment with metformin, with or without sulfonylureas, at ₹200-600. Oral combinations with newer drugs run ₹800-2,500, and insulin-based treatment with basic monitoring and supplies ₹1,500-4,500. GLP-1 receptor agonists can cost several thousand rupees or more. Dr Praveen Kumar of SRM Prime Hospital, Chennai, estimates that urban outpatients with Type 2 diabetes spend ₹2,000-5,000 a month, rising to ₹8,000-15,000 on advanced regimens. He notes that this spending is largely out of pocket.
When money runs short, patients ration care. Dr Praveen says some skip doses, take tablets on alternate days or stop altogether. Some arrive for consultations without current HbA1c or kidney function reports and rely on a fasting glucose reading. Poorer patients may come to hospital only after symptoms or complications appear. Dr Nishchitha describes patients paying for either medicines or tests because they cannot afford both, and calls it a vicious circle: poorly controlled diabetes raises the risk of complications, which makes care more expensive. Dr Shankar V of Apollo Hospitals, Seshadripuram, says medicines should not be stopped regardless of socio-economic status, because early and consistent treatment prevents costly complications.
The choice of drug matters. Metformin and sulfonylureas control blood glucose effectively at low cost. SGLT2 inhibitors and GLP-1 agonists may add heart or kidney benefits for selected patients but cost more. Dr Nishchitha says quality-assured generics can cut spending when clinically suitable and reliably available, and that the aim is the most effective treatment a patient can realistically continue. Dr Shankar agrees that well-studied generics can be safe, though older drugs may lack the added benefits.
Insulin brings its own costs. Dr Ravikiran of SIMS Hospital, Chennai, says older human insulin is inexpensive, while newer formulations cost two to three times as much per unit, around ₹3.30. Storage is harder for people without reliable refrigeration or electricity. He estimates imported GLP-1 drugs at ₹9,000-13,000 a month against ₹3,000-4,000 for locally made generics, or roughly ₹24,000 for six months. Annual screening of the heart, nerves, kidneys and eyes, he says, costs ₹3,000-4,000. Dr Shankar considers HbA1c testing every three months ideal, with six months acceptable when cost is a constraint.
Complications change the scale of spending. Dr Ravikiran puts retinopathy injections at ₹25,000-30,000, often repeated over months, and private dialysis at ₹20,000-25,000 a month; subsidised centres cost less, though consumables are still charged. Foot problems can mean repeated wound care, surgery and amputation. Lost wages add to the burden, especially for daily-wage workers, as do travel from rural areas and relatives cutting their work hours to provide care.
The clinicians' proposals converge: reliable generics, subsidised insulin, stronger primary care, and HbA1c, kidney, retinal and foot checks built into routine services. Dr Nishchitha also argues that financial protection schemes should cover outpatient care, where most diabetes spending occurs. The open question is whether families can sustain that spending for decades.
Bemerkenswerte Zitate
The goal is not simply to prescribe the cheapest medicine. It is to prescribe the most effective treatment that the patient can realistically continue.— Dr Nishchitha K, Gleneagles BGS Hospital, Bengaluru
When the actual complications happen, the cost spirals up.— Dr Ravikiran, SIMS Hospital, Chennai
Möchten Sie die ganze Geschichte?
Das Original lesen bei The South First ↗